Literature DB >> 17195040

[Peripheral NK/T-cell lymphoma].

T Rüdiger1, A Zettl, P Adam, I Bonzheim, E Geissinger, H K Müller-Hermelink.   

Abstract

Peripheral T-cell lymphomas comprise 8% of the malignant lymphomas in Germany. About 25% of these cases present primarily in extranodal localizations. Such localizations are typical for the respective disease and form the basis for the classification of extranodal peripheral T-cell lymphoma. The morphology, immunophenotype and lineage specificity of the tumor cells (originating from T- or NK-cells) is only secondary for the classification. Extranodal NK/T-cell lymphomas of the nasal type are characterized by an angiocentric growth pattern and large confluent areas of necrosis. In addition, there is a clonal infection by Epstein-Barr virus in the T-lymphocytes. In the differential diagnosis, B-cell lymphomas are more frequent at all localizations than T- or NK-cell lymphomas.

Entities:  

Mesh:

Year:  2007        PMID: 17195040     DOI: 10.1007/s00292-006-0879-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  14 in total

1.  Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin.

Authors:  A K Chiang; G Srivastava; P W Lau; F C Ho
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

2.  Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas.

Authors:  W Haedicke; F C Ho; A Chott; L Moretta; T Rüdiger; G Ott; H K Müller-Hermelink
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

3.  Nasal T-cell lymphoma associated with hemophagocytic syndrome.

Authors:  C S Ng; J K Chan; P N Cheng; S C Szeto
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

4.  Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.

Authors:  A K Chiang; Q Tao; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

5.  Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Angen Liu; Tetsuya Takakuwa; Wen-Juan Luo; Shigeki Fujita; Katsuyuki Aozasa
Journal:  Cancer Sci       Date:  2006-07       Impact factor: 6.716

6.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

Authors:  T Rüdiger; D D Weisenburger; J R Anderson; J O Armitage; J Diebold; K A MacLennan; B N Nathwani; F Ullrich; H K Müller-Hermelink
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

7.  Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.

Authors:  Yu Zhang; Hiroshi Nagata; Tatsuro Ikeuchi; Hiroyuki Mukai; Michiko K Oyoshi; Ayako Demachi; Tomohiro Morio; Hiroshi Wakiguchi; Nobuhiro Kimura; Norio Shimizu; Kohtaro Yamamoto
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

8.  Classification of cytotoxic T-cell and natural killer cell lymphomas.

Authors:  Elaine S Jaffe; Laszlo Krenacs; Mark Raffeld
Journal:  Semin Hematol       Date:  2003-07       Impact factor: 3.851

9.  Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.

Authors:  S Nakamura; T Suchi; T Koshikawa; K Kitoh; K Koike; H Komatsu; S Iida; Y Kagami; M Ogura; E Katoh
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.